Fig. 10From: The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in GermanyAdditive Premiums & AnTC of subgroup-weighted ACT. The figure depicts the additive premiums in contrast to the annual therapeutic costs of subgroup-weighted appropriate comparative therapiesBack to article page